Significance of capsular attachment and invasion of cancer tissues in prostate cancer

International Journal of Urology

Volumn 10, Issue 6, 2003, Pages 309-314

  Tanaka, Masashi ^a   Suzuki, Noriyuki ^a   Nakatsu, Hiroomi ^a   Murakami, Shino ^a   Matsuzaki, Osamu ^b   Shimazaki, Jun ^c  

^a ASAHI GENERAL HOSPITAL   (Japan)

^b KIMITSU CHUO HOSPITAL   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Capsular invasion; Capsular penetration; Prostate cancer; Staging; T factor

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CANCER MORTALITY; CANCER TISSUE; FOLLOW UP; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; KIDNEY CAPSULE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; SEMINAL VESICLE;

AGED; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0038121521     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2003.00630.x     Document Type: Article

References (35)

1. Sobin LH, Wittekind Ch. TNM Classification of Malignant Tumours, 5th edn. Wiley-Liss, New York 1997, 170-3.
2. American Joint Committee on Cancer. AJCC Cancer Staging Handbook, 5th edn. Lippincott-Raven, Philadelphia 1998, 203-7.
3. Japanese Urological Association, The Japanese Pathological Society. General Rule for Clinical and Pathological Studies on Prostate Cancer, 3rd edn. Kanehara, Tokyo 2001. (In Japanese.)
4. Stamey TA, McNeal JE, Freiha FS, Redwine E. Morpholometric and clinical studies on 68 consecutive radical prostatectomies. J. Urol. 1988; 139: 1235-41.
5. Gleason DF, Mellinger GT, Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J. Urol. 1974; 111: 58-64.
6. The Research Group for Population-based Cancer Registration in Japan. Cancer incidence in Japan. Gann Monograph on Cancer Research. Japan Scientific Societies Press, Tokyo 1999, 83-143.
7. Partin AW, Epstein JI, Cho KR, Gittelsohn AM, Walsh PC. Morphometric measurement of tumor volume and percent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer. J. Urol. 1989; 141: 341-5.
8. Wheeler TM, Dillioglugil O, Kattan MW et al. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Human Pathol. 1998; 29: 856-62.
9. Epstein JI, Partin AW, Suavageot J, Walsh PC. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am. J. Surg. Pathol. 1996; 20: 286-92.
10. van den Ouden D, Schroeder FH. Management of locally advanced prostate cancer. World J. Urol. 2000; 18: 194-203.
11. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Feiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986; 11: 60-3.
12. Epstein JI, Carmichael M, Partin AW, Walsh PC. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J. Urol. 1993; 149: 1478-8.
13. Humphrey PA, Vollmer RT. Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. Mod. Pathol. 1997; 10: 326-33.
14. Epstein JI, Sauvageot J. Do close but negative margins in radical prostatectomy specimens increase the risk of postoperative progression? J. Urol. 1997; 157: 241-3.
15. Cheng L, Darson MF, Bergstralh EJ, Slezak J, Myers RP, Boswick DG. Correlation of margin status and extraprostatic extension with progression of prostate carcinoma. Cancer 1999; 86: 1775-82.
16. Blute ML, Bostwick DG, Seay TM et al. Pathologic classification of prostate carcinoma. Cancer 1998; 82: 902-8.
17. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J. Urol. 1995; 154: 1818-24.
18. Gerber GS, Thisted RA, Scardino PT et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 1996; 28: 615-9.
19. Bostwick DG, Qian J, Bergstralh E et al. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J. Urol. 1996; 155: 1361-7.
20. van den Ouden D, Kranse R, Hop WC, van der Kwast TH, Schroeder FH. Microvascular invasion in prostate cancer: prognostic significance in patients treated by radical prostatectomy for clinically localized carcinoma. Urol. Int. 1998; 60: 17-24.
21. Stamey TA, Sozen TS, Yemoto CM, McNeal JE. Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: Common grouped for therapeutic trials and TNM subgroups. J. Urol. 1998; 159: 2009-12.
22. Easham JA, Scardino PT. Radical prostatectomy. In: Walsh PC, Retik AB, Vauyghan ED Jr, Wein AJ (eds). Campbell's Urology, Vol. 3. 7th edn, W.B. Saunders Co, Philadelphia 1998, 2547-64.
23. Ramos CG, Carvalhal GF, Smith DS, Mager DE, Catalona WJ. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer. J. Urol. 1999; 161: 1525-9.
24. Egawa S, Suyama K, Arai Y et al. Treatment outcome by risk group after radical prostatectomy in Japanese men. Int. J. Urol. 2001; 8: 295-300.
25. Tefilli MV, Wood DP Jr. Clinical-pathologic T3NxM0 prostate cancer: The case for surgery. In: Resnick MI, Thompson IM (eds.) Advanced Therapy of Prostate Disease, BC Decker, Hamilton 2000, 291-9.
26. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J. Urol. 1994; 152: 1831-6.
27. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. New Engl. J. Med. 1999; 341: 1781-8.
28. Zlotta AR, Schulman CC. Neoadjuvant and adjuvant hormone therapy for prostate cancer. World J. Urol. 2000; 18: 179-82.
29. Froehner WM. A review of studies of hormonal adjuvant therapy in prostate cancer. Urol 1999; 36 (Suppl. 2): 14-9.
30. Grimm MO, Kamphausen S, Hugenschmidt H, Stephan-Odenthal M, Ackermann R, Vogeli TA. Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur. Urol. 2002; 41: 628-34.
31. Clark PE, Levin HS, Kupelian PA, Reddy C, Zippe CD, Klein EA. Intermediate-term outcome with radical prostatectomy for localized prostate cancer: The Cleveland clinic experience. Prostate J. 2001; 3:118-25.
32. Cagiannos I, Graefen M, Karakiewicz PI et al. Analysis of clinical stage T2 prostate cancer: Do current subclassifications represent an improvement? J. Clin. Oncol. 2002; 20: 2025-30.
33. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J. Urol. 2002; 167: 528-34.
34. Sobin LH, Wittekind Ch. TNM Classification of Malignant Tumours, 6th edn. Wiley-Liss, New York 2002, 184-7.
35. American Joint Committee on Cancer. AJCC Cancer Staging Manual, 6th edn. Springer, New York 2002, 309-16.